37 results on '"Mohammadi, Moosa"'
Search Results
2. Structural basis for FGF hormone signalling
- Author
-
Chen, Lingfeng, Fu, Lili, Sun, Jingchuan, Huang, Zhiqiang, Fang, Mingzhen, Zinkle, Allen, Liu, Xin, Lu, Junliang, Pan, Zixiang, Wang, Yang, Liang, Guang, Li, Xiaokun, Chen, Gaozhi, and Mohammadi, Moosa
- Abstract
α/βKlotho coreceptors simultaneously engage fibroblast growth factor (FGF) hormones (FGF19, FGF21 and FGF23)1,2and their cognate cell-surface FGF receptors (FGFR1–4) thereby stabilizing the endocrine FGF–FGFR complex3–6. However, these hormones still require heparan sulfate (HS) proteoglycan as an additional coreceptor to induce FGFR dimerization/activation and hence elicit their essential metabolic activities6. To reveal the molecular mechanism underpinning the coreceptor role of HS, we solved cryo-electron microscopy structures of three distinct 1:2:1:1 FGF23–FGFR–αKlotho–HS quaternary complexes featuring the ‘c’ splice isoforms of FGFR1 (FGFR1c), FGFR3 (FGFR3c) or FGFR4 as the receptor component. These structures, supported by cell-based receptor complementation and heterodimerization experiments, reveal that a single HS chain enables FGF23 and its primary FGFR within a 1:1:1 FGF23–FGFR–αKlotho ternary complex to jointly recruit a lone secondary FGFR molecule leading to asymmetric receptor dimerization and activation. However, αKlotho does not directly participate in recruiting the secondary receptor/dimerization. We also show that the asymmetric mode of receptor dimerization is applicable to paracrine FGFs that signal solely in an HS-dependent fashion. Our structural and biochemical data overturn the current symmetric FGFR dimerization paradigm and provide blueprints for rational discovery of modulators of FGF signalling2as therapeutics for human metabolic diseases and cancer.
- Published
- 2023
- Full Text
- View/download PDF
3. Fibroblast growth factor signalling in osteoarthritis and cartilage repair
- Author
-
Xie, Yangli, Zinkle, Allen, Chen, Lin, and Mohammadi, Moosa
- Abstract
Regulated fibroblast growth factor (FGF) signalling is a prerequisite for the correct development and homeostasis of articular cartilage, as evidenced by the fact that aberrant FGF signalling contributes to the maldevelopment of joints and to the onset and progression of osteoarthritis. Of the four FGF receptors (FGFRs 1–4), FGFR1 and FGFR3 are strongly implicated in osteoarthritis, and FGFR1 antagonists, as well as agonists of FGFR3, have shown therapeutic efficacy in mouse models of spontaneous and surgically induced osteoarthritis. FGF18, a high affinity ligand for FGFR3, is the only FGF-based drug currently in clinical trials for osteoarthritis. This Review covers the latest advances in our understanding of the molecular mechanisms that regulate FGF signalling during normal joint development and in the pathogenesis of osteoarthritis. Strategies for FGF signalling-based treatment of osteoarthritis and for cartilage repair in animal models and clinical trials are also introduced. An improved understanding of FGF signalling from a structural biology perspective, and of its roles in skeletal development and diseases, could unlock new avenues for discovery of modulators of FGF signalling that can slow or stop the progression of osteoarthritis.
- Published
- 2020
- Full Text
- View/download PDF
4. Molecular basis for receptor tyrosine kinase A-loop tyrosine transphosphorylation
- Author
-
Chen, Lingfeng, Marsiglia, William M., Chen, Huaibin, Katigbak, Joseph, Erdjument-Bromage, Hediye, Kemble, David J., Fu, Lili, Ma, Jinghong, Sun, Gongqin, Zhang, Yingkai, Liang, Guang, Neubert, Thomas A., Li, Xiaokun, Traaseth, Nathaniel J., and Mohammadi, Moosa
- Abstract
A long-standing mystery shrouds the mechanism by which catalytically repressed receptor tyrosine kinase domains accomplish transphosphorylation of activation loop (A-loop) tyrosines. Here we show that this reaction proceeds via an asymmetric complex that is thermodynamically disadvantaged because of an electrostatic repulsion between enzyme and substrate kinases. Under physiological conditions, the energetic gain resulting from ligand-induced dimerization of extracellular domains overcomes this opposing clash, stabilizing the A-loop-transphosphorylating dimer. A unique pathogenic fibroblast growth factor receptor gain-of-function mutation promotes formation of the complex responsible for phosphorylation of A-loop tyrosines by eliminating this repulsive force. We show that asymmetric complex formation induces a more phosphorylatable A-loop conformation in the substrate kinase, which in turn promotes the active state of the enzyme kinase. This explains how quantitative differences in the stability of ligand-induced extracellular dimerization promotes formation of the intracellular A-loop-transphosphorylating asymmetric complex to varying extents, thereby modulating intracellular kinase activity and signaling intensity.
- Published
- 2020
- Full Text
- View/download PDF
5. Sustained remission of type 2 diabetes in rodents by centrally administered fibroblast growth factor 4.
- Author
-
Sun, Hongbin, Lin, Wei, Tang, Yu, Tu, Hongqing, Chen, Ting, Zhou, Jie, Wang, Dezhong, Xu, Qingqing, Niu, Jianlou, Dong, Wenliya, Liu, Sidan, Ni, Xinyan, Yang, Wen, Zhao, Yingzheng, Ying, Lei, Zhang, Jie, Li, Xiaokun, Mohammadi, Moosa, Shen, Wei L., and Huang, Zhifeng
- Abstract
Type 2 diabetes (T2D) is a major health and economic burden worldwide. Despite the availability of multiple drugs for short-term management, sustained remission of T2D is currently not achievable pharmacologically. Intracerebroventricular administration of fibroblast growth factor 1 (icvFGF1) induces sustained remission in T2D rodents, propelling intense research efforts to understand its mechanism of action. Whether other FGFs possess similar therapeutic benefits is currently unknown. Here, we show that icvFGF4 also elicits a sustained antidiabetic effect in both male db / db mice and diet-induced obese mice by activating FGF receptor 1 (FGFR1) expressed in glucose-sensing neurons within the mediobasal hypothalamus. Specifically, FGF4 excites glucose-excited (GE) neurons while inhibiting glucose-inhibited (GI) neurons. Moreover, icvFGF4 restores the percentage of GI neurons in db / db mice. Importantly, intranasal delivery of FGF4 alleviates hyperglycemia in db / db mice, paving the way for non-invasive therapy. We conclude that icvFGF4 holds significant therapeutic potential for achieving sustained remission of T2D. [Display omitted] • Centrally administrated FGF4 elicits a sustained diabetic remission in T2D mice • GSNs within the mediobasal hypothalamus are the cellular targets of FGF4 • FGF4 exerts sustained anti-hyperglycemic effect by activating FGFR1 in GSNs • Intranasal administration of FGF4 could achieve long-term antidiabetic remission Sun et al. identified FGF4 as a potent and sustained antidiabetic factor in diabetic mice following both intracerebroventricular and intranasal administration. This sheds light on a potential therapeutic strategy for achieving sustained remission of type 2 diabetes and related metabolic disorders. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
6. α-Klotho is a non-enzymatic molecular scaffold for FGF23 hormone signalling
- Author
-
Chen, Gaozhi, Liu, Yang, Goetz, Regina, Fu, Lili, Jayaraman, Seetharaman, Hu, Ming-Chang, Moe, Orson W., Liang, Guang, Li, Xiaokun, and Mohammadi, Moosa
- Abstract
The ageing suppressor α-klotho binds to the fibroblast growth factor receptor (FGFR). This commits FGFR to respond to FGF23, a key hormone in the regulation of mineral ion and vitamin D homeostasis. The role and mechanism of this co-receptor are unknown. Here we present the atomic structure of a 1:1:1 ternary complex that consists of the shed extracellular domain of α-klotho, the FGFR1c ligand-binding domain, and FGF23. In this complex, α-klotho simultaneously tethers FGFR1c by its D3 domain and FGF23 by its C-terminal tail, thus implementing FGF23–FGFR1c proximity and conferring stability. Dimerization of the stabilized ternary complexes and receptor activation remain dependent on the binding of heparan sulfate, a mandatory cofactor of paracrine FGF signalling. The structure of α-klotho is incompatible with its purported glycosidase activity. Thus, shed α-klotho functions as an on-demand non-enzymatic scaffold protein that promotes FGF23 signalling.
- Published
- 2018
- Full Text
- View/download PDF
7. Fibroblast growth factor 1 ameliorates diabetic nephropathy by an anti-inflammatory mechanism
- Author
-
Liang, Guang, Song, Lintao, Chen, Zilu, Qian, Yuanyuan, Xie, Junjun, Zhao, Longwei, Lin, Qian, Zhu, Guanghui, Tan, Yi, Li, Xiaokun, Mohammadi, Moosa, and Huang, Zhifeng
- Abstract
Inflammation plays a central role in the etiology of diabetic nephropathy, a global health issue. We observed a significant reduction in the renal expression of fibroblast growth factor 1, a known mitogen and insulin sensitizer, in patients with diabetic nephropathy and in mouse models implying that fibroblast growth factor 1 possesses beneficial anti-inflammatory and renoprotective activities in vivo. To test this possibility, we investigated the effects of chronic intraperitoneal administration of fibroblast growth factor 1 into both the streptozotocin-induced type 1 diabetes and db/dbtype 2 diabetes models. Indeed, recombinant fibroblast growth factor 1 significantly suppressed renal inflammation (i.e., cytokines, macrophage infiltration), glomerular and tubular damage, and renal dysfunction in both type 1 and type 2 diabetes mice. Fibroblast growth factor 1 was able to correct the elevated blood glucose levels in type 2 but not in type 1 diabetic mice, suggesting that the anti-inflammatory effect of fibroblast growth factor 1 was independent of its glucose-lowering activity. The mechanistic study demonstrated that fibroblast growth factor 1–mediated inhibition of the renal inflammation in vivowas accompanied by attenuation of the nuclear factor κB and c-Jun N-terminal kinase signaling pathways, further validated in vitrousing cultured glomerular mesangial cells and podocytes. Thus, fibroblast growth factor 1 holds great promise for developing new treatments for diabetic nephropathy through countering inflammatory signaling cascades in injured renal tissue.
- Published
- 2018
- Full Text
- View/download PDF
8. Uncoupling the Mitogenic and Metabolic Functions of FGF1 by Tuning FGF1-FGF Receptor Dimer Stability
- Author
-
Huang, Zhifeng, Tan, Yi, Gu, Junlian, Liu, Yang, Song, Lintao, Niu, Jianlou, Zhao, Longwei, Srinivasan, Lakshmi, Lin, Qian, Deng, Jingjing, Li, Yang, Conklin, Daniel J., Neubert, Thomas A., Cai, Lu, Li, Xiaokun, and Mohammadi, Moosa
- Abstract
The recent discovery of metabolic roles for fibroblast growth factor 1 (FGF1) in glucose homeostasis has expanded the functions of this classically known mitogen. To dissect the molecular basis for this functional pleiotropy, we engineered an FGF1 partial agonist carrying triple mutations (FGF1ΔHBS) that diminished its ability to induce heparan sulfate (HS)-assisted FGF receptor (FGFR) dimerization and activation. FGF1ΔHBSexhibited a severely reduced proliferative potential, while preserving the full metabolic activity of wild-type FGF1 in vitro and in vivo. Hence, suboptimal FGFR activation by a weak FGF1-FGFR dimer is sufficient to evoke a metabolic response, whereas full FGFR activation by stable and sustained dimerization is required to elicit a mitogenic response. In addition to providing a physical basis for the diverse activities of FGF1, our findings will impact ongoing drug discoveries targeting FGF1 and related FGFs for the treatment of a variety of human diseases.
- Published
- 2017
- Full Text
- View/download PDF
9. Congenital hypogonadotropic hypogonadism with split hand/foot malformation: a clinical entity with a high frequency of FGFR1 mutations
- Author
-
Villanueva, Carine, Jacobson-Dickman, Elka, Xu, Cheng, Manouvrier, Sylvie, Dwyer, Andrew A., Sykiotis, Gerasimos P., Beenken, Andrew, Liu, Yang, Tommiska, Johanna, Hu, Youli, Tiosano, Dov, Gerard, Marion, Leger, Juliane, Drouin-Garraud, Valérie, Lefebvre, Hervé, Polak, Michel, Carel, Jean-Claude, Phan-Hug, Franziska, Hauschild, Michael, Plummer, Lacey, Rey, Jean-Pierre, Raivio, Taneli, Bouloux, Pierre, Sidis, Yisrael, Mohammadi, Moosa, de Roux, Nicolas, and Pitteloud, Nelly
- Abstract
Purpose:Congenital hypogonadotropic hypogonadism (CHH) and split hand/foot malformation (SHFM) are two rare genetic conditions. Here we report a clinical entity comprising the two.Methods:We identified patients with CHH and SHFM through international collaboration. Probands and available family members underwent phenotyping and screening for FGFR1 mutations. The impact of identified mutations was assessed by sequence- and structure-based predictions and/or functional assays.Results:We identified eight probands with CHH with (n = 3; Kallmann syndrome) or without anosmia (n = 5) and SHFM, seven of whom (88%) harbor FGFR1 mutations. Of these seven, one individual is homozygous for p.V429E and six individuals are heterozygous for p.G348R, p.G485R, p.Q594*, p.E670A, p.V688L, or p.L712P. All mutations were predicted by in silico analysis to cause loss of function. Probands with FGFR1 mutations have severe gonadotropin-releasing hormone deficiency (absent puberty and/or cryptorchidism and/or micropenis). SHFM in both hands and feet was observed only in the patient with the homozygous p.V429E mutation; V429 maps to the fibroblast growth factor receptor substrate 2a binding domain of FGFR1, and functional studies of the p.V429E mutation demonstrated that it decreased recruitment and phosphorylation of fibroblast growth factor receptor substrate 2a to FGFR1, thereby resulting in reduced mitogen-activated protein kinase signaling.Conclusion:FGFR1 should be prioritized for genetic testing in patients with CHH and SHFM because the likelihood of a mutation increases from 10% in the general CHH population to 88% in these patients.Genet Med 17 8, 651–659.
- Published
- 2015
- Full Text
- View/download PDF
10. FGF21 mediates alcohol-induced adipose tissue lipolysis by activation of systemic release of catecholamine in mice[S]
- Author
-
Zhao, Cuiqing, Liu, Yanlong, Xiao, Jian, Liu, Liming, Chen, Shaoyu, Mohammadi, Moosa, McClain, Craig J., Li, Xiaokun, and Feng, Wenke
- Abstract
Alcohol consumption leads to adipose tissue lipoatrophy and mobilization of FFAs, which contributes to hepatic fat accumulation in alcoholic liver disease. This study aimed to investigate the role of fibroblast growth factor (FGF)21, a metabolic regulator, in the regulation of chronic-binge alcohol-induced adipose tissue lipolysis. FGF21 KO mice were subjected to chronic-binge alcohol exposure, and epididymal white adipose tissue lipolysis and liver steatosis were investigated. Alcohol exposure caused adipose intracellular cAMP elevation and activation of lipolytic enzymes, leading to FFA mobilization in both WT and FGF21 KO mice. However, alcohol-induced systemic elevation of catecholamine, which is known to be a major player in adipose lipolysis by binding to the β-adrenergic receptor, was markedly inhibited in KO mice. Supplementation with recombinant human FGF21 to alcohol-exposed FGF21 KO mice resulted in an increase in fat loss in parallel with an increase of circulating norepinephrine concentration. Furthermore, alcohol consumption-induced fatty liver was blunted in the KO mice, indicating an inhibition of fatty acid reverse transport from adipose to the liver in the KO mice. Taken together, our studies demonstrate that FGF21 KO mice are protected from alcohol-induced adipose tissue excess-lipolysis through a mechanism involving systemic catecholamine release.
- Published
- 2015
- Full Text
- View/download PDF
11. DFG-out Mode of Inhibition by an Irreversible Type-1 Inhibitor Capable of Overcoming Gate-Keeper Mutations in FGF Receptors
- Author
-
Huang, Zhifeng, Tan, Li, Wang, Huiyan, Liu, Yang, Blais, Steven, Deng, Jingjing, Neubert, Thomas A., Gray, Nathanael S., Li, Xiaokun, and Mohammadi, Moosa
- Abstract
Drug-resistance acquisition through kinase gate-keeper mutations is a major hurdle in the clinic. Here, we determined the first crystal structures of the human FGFR4 kinase domain (FGFR4K) alone and complexed with ponatinib, a promiscuous type-2 (DFG-out) kinase inhibitor, and an oncogenic FGFR4K harboring the V550L gate-keeper mutation bound to FIIN-2, a new type-1 irreversible inhibitor. Remarkably, like ponatinib, FIIN-2 also binds in the DFG-out mode despite lacking a functional group necessary to occupy the pocket vacated upon the DFG-out flip. Structural analysis reveals that the covalent bond between FIIN-2 and a cysteine, uniquely present in the glycine-rich loop of FGFR kinases, facilitates the DFG-out conformation, which together with the internal flexibility of FIIN-2 enables FIIN-2 to avoid the steric clash with the gate-keeper mutation that causes the ponatinib resistance. The structural data provide a blueprint for the development of next generation anticancer inhibitors through combining the salient inhibitory mechanisms of ponatinib and FIIN-2.
- Published
- 2015
- Full Text
- View/download PDF
12. Compositional Analysis of Heparin/Heparan Sulfate Interacting with Fibroblast Growth Factor Fibroblast Growth Factor Receptor Complexes.
- Author
-
Fuming Zhang, Zhenqing Zhang, Xinfu Lin, Beenken, Andrew, Eliseenkova, Anna V., Mohammadi, Moosa, and Linhardt, Robert J.
- Published
- 2009
- Full Text
- View/download PDF
13. Inhibition of Growth Hormone Signaling by the Fasting-Induced Hormone FGF21.
- Author
-
Inagaki, Takeshi, Lin, Vicky Y., Goetz, Regina, Mohammadi, Moosa, Mangelsdorf, David J., and Kliewer, Steven A.
- Subjects
HEREDITY ,ETIOLOGY of diseases ,ORGANIC compounds ,AMINO acids - Abstract
Summary: Starvation blocks the actions of growth hormone (GH) and inhibits growth through mechanisms that are not well understood. In this report, we demonstrate that fibroblast growth factor 21 (FGF21), a hormone induced by fasting, causes GH resistance. In liver, FGF21 reduces concentrations of the active form of signal transducer and activator of transcription 5 (STAT5), a major mediator of GH actions, and causes corresponding decreases in the expression of its target genes, including insulin-like growth factor 1 (IGF-1). FGF21 also induces hepatic expression of IGF-1 binding protein 1 and suppressor of cytokine signaling 2, which blunt GH signaling. Chronic exposure to FGF21 markedly inhibits growth in mice. These data suggest a central role for FGF21 in inhibiting growth as part of its broader role in inducing the adaptive response to starvation. [Copyright &y& Elsevier]
- Published
- 2008
- Full Text
- View/download PDF
14. Endocrine Regulation of the Fasting Response by PPARα-Mediated Induction of Fibroblast Growth Factor 21.
- Author
-
Inagaki, Takeshi, Dutchak, Paul, Zhao, Guixiang, Ding, Xunshan, Gautron, Laurent, Parameswara, Vinay, Li, Yong, Goetz, Regina, Mohammadi, Moosa, Esser, Victoria, Elmquist, Joel K., Gerard, Robert D., Burgess, Shawn C., Hammer, Robert E., Mangelsdorf, David J., and Kliewer, Steven A.
- Subjects
FIBROBLAST growth factors ,NUCLEAR receptors (Biochemistry) ,ENDOCRINE glands ,FASTING - Abstract
Summary: Peroxisome proliferator-activated receptor α (PPARα) regulates the utilization of fat as an energy source during starvation and is the molecular target for the fibrate dyslipidemia drugs. Here, we identify the endocrine hormone fibroblast growth factor 21 (FGF21) as a mediator of the pleiotropic actions of PPARα. FGF21 is induced directly by PPARα in liver in response to fasting and PPARα agonists. FGF21 in turn stimulates lipolysis in white adipose tissue and ketogenesis in liver. FGF21 also reduces physical activity and promotes torpor, a short-term hibernation-like state of regulated hypothermia that conserves energy. These findings demonstrate an unexpected role for the PPARα-FGF21 endocrine signaling pathway in regulating diverse metabolic and behavioral aspects of the adaptive response to starvation. [Copyright &y& Elsevier]
- Published
- 2007
- Full Text
- View/download PDF
15. Kinetic Model for FGF, FGFR, and Proteoglycan Signal Transduction Complex Assembly.
- Author
-
Ibrahimi, Omar A., Zhang, Fuming, Hrstka, Sybil C. Lang, Mohammadi, Moosa, and Linhard, Robert J.
- Published
- 2004
- Full Text
- View/download PDF
16. Cracking the Molecular Origin of Intrinsic Tyrosine Kinase Activity through Analysis of Pathogenic Gain-of-Function Mutations
- Author
-
Chen, Huaibin, Huang, Zhifeng, Dutta, Kaushik, Blais, Steven, Neubert, Thomas A., Li, Xiaokun, Cowburn, David, Traaseth, Nathaniel J., and Mohammadi, Moosa
- Abstract
The basal (ligand-independent) kinase activity of receptor tyrosine kinases (RTKs) promotes trans-phosphorylation on activation loop tyrosines upon ligand-induced receptor dimerization, thus upregulating intrinsic kinase activity and triggering intracellular signaling. To understand the molecular determinants of intrinsic kinase activity, we used X-ray crystallography and NMR spectroscopy to analyze pathogenic FGF receptor mutants with gradations in gain-of-function activity. These structural analyses revealed a “two-state” dynamic equilibrium model whereby the kinase toggles between an “inhibited,” structurally rigid ground state and a more dynamic and heterogeneous active state. The pathogenic mutations have different abilities to shift this equilibrium toward the active state. The increase in the fractional population of FGF receptors in the active state correlates with the degree of gain-of-function activity and clinical severity. Our data demonstrate that the fractional population of RTKs in the active state determines intrinsic kinase activity and underscore how a slight increase in the active population of kinases can have grave consequences for human health.
- Published
- 2013
- Full Text
- View/download PDF
17. Regulation of serum 1,25(OH)2Vitamin D3levels by fibroblast growth factor 23 is mediated by FGF receptors 3 and 4
- Author
-
Gattineni, Jyothsna, Twombley, Katherine, Goetz, Regina, Mohammadi, Moosa, and Baum, Michel
- Abstract
Fibroblast growth factor 23 (FGF23) is a phosphaturic hormone implicated in the pathogenesis of several hypophosphatemic disorders. FGF23 causes hypophosphatemia by decreasing the expression of sodium phosphate cotransporters (NaPi-2a and NaPi-2c) and decreasing serum 1,25(OH)2Vitamin D3levels. We previously showed that FGFR1 is the predominant receptor for the hypophosphatemic actions of FGF23 by decreasing renal NaPi-2a and 2c expression while the receptors regulating 1,25(OH)2Vitamin D3levels remained elusive. To determine the FGFRs regulating 1,25(OH)2Vitamin D3levels, we studied FGFR3−/−FGFR4−/−mice as these mice have shortened life span and are growth retarded similar to FGF23−/−and Klotho−/−mice. Baseline serum 1,25(OH)2Vitamin D3levels were elevated in the FGFR3−/−FGFR4−/−mice compared with wild-type mice (102.2 ± 14.8 vs. 266.0 ± 34.0 pmol/l; P= 0.001) as were the serum levels of FGF23. Administration of recombinant FGF23 had no effect on serum 1,25(OH)2Vitamin D3in the FGFR3−/−FGFR4−/−mice (173.4 ± 32.7 vs. 219.7 ± 56.5 pmol/l; vehicle vs. FGF23) while it reduced serum 1,25(OH)2Vitamin D3levels in wild-type mice. Administration of FGF23 to FGFR3−/−FGFR4−/−mice resulted in a decrease in serum parathyroid hormone (PTH) levels and an increase in serum phosphorus levels mediated by increased renal phosphate reabsorption. These data indicate that FGFR3 and 4 are the receptors that regulate serum 1,25(OH)2Vitamin D3levels in response to FGF23. In addition, when 1,25(OH)2Vitamin D3levels are not affected by FGF23, as in FGFR3−/−FGFR4−/−mice, a reduction in PTH can override the effects of FGF23 on renal phosphate transport.
- Published
- 2011
- Full Text
- View/download PDF
18. Aggregation-induced activation of the epidermal growth factor receptor protein tyrosine kinase.
- Author
-
Mohammadi, Moosa and Honeger, Annemarie
- Published
- 1993
- Full Text
- View/download PDF
19. Nonsense Mutations in FGF8 Gene Causing Different Degrees of Human Gonadotropin-Releasing Deficiency
- Author
-
Trarbach, Ericka B., Abreu, Ana Paula, Silveira, Leticia Ferreira Gontijo, Garmes, Heraldo Mendes, Baptista, Maria Tereza M., Teles, Milena Gurgel, Costa, Elaine M. F., Mohammadi, Moosa, Pitteloud, Nelly, Mendonca, Berenice B., and Latronico, Ana Claudia
- Abstract
CONTEXT: FGFR1 mutations cause isolated hypogonadotropic hypogonadism (IHH) with or without olfactory abnormalities, Kallmann syndrome, and normosmic IHH respectively. Recently, missense mutations in FGF8, a key ligand for fibroblast growth factor receptor (FGFR) 1 in the ontogenesis of GnRH, were identified in IHH patients, thus establishing FGF8 as a novel locus for human GnRH deficiency. OBJECTIVE: Our objective was to analyze the clinical, hormonal, and molecular findings of two familial IHH patients due to FGF8 gene mutations. METHODS: and Patients: The entire coding region of the FGF8 gene was amplified and sequenced in two well-phenotyped IHH probands and their relatives. RESULTS: Two unique heterozygous nonsense mutations in FGF8 (p.R127X and p.R129X) were identified in two unrelated IHH probands, which were absent in 150 control individuals. These two mutations, mapped to the core domain of FGF8, impact all four human FGF8 isoforms, and lead to the deletion of a large portion of the protein, generating nonfunctional FGF8 ligands. The p.R127X mutation was identified in an 18-yr-old Kallmann syndrome female. Her four affected siblings with normosmic IHH or delayed puberty also carried the p.R127X mutation. Additional developmental anomalies, including cleft lip and palate and neurosensorial deafness, were also present in this family. The p.R129X mutation was identified in a 30-yr-old man with familial normosmic IHH and severe GnRH deficiency. CONCLUSIONS: We identified the first nonsense mutations in the FGF8 gene in familial IHH with variable degrees of GnRH deficiency and olfactory phenotypes, confirming that loss-of-function mutations in FGF8 cause human GnRH deficiency.
- Published
- 2010
20. FGF23 decreases renal NaPi-2a and NaPi-2c expression and induces hypophosphatemia in vivo predominantly via FGF receptor 1
- Author
-
Gattineni, Jyothsna, Bates, Carlton, Twombley, Katherine, Dwarakanath, Vangipuram, Robinson, Michael L., Goetz, Regina, Mohammadi, Moosa, and Baum, Michel
- Abstract
Fibroblast growth factor-23 (FGF23) is a phosphaturic hormone that contributes to several hypophosphatemic disorders by reducing the expression of the type II sodium-phosphate cotransporters (NaPi-2a and NaPi-2c) in the kidney proximal tubule and by reducing serum 1,25-dihydroxyvitamin D3[1,25(OH)2D3] levels. The FGF receptor(s) mediating the hypophosphatemic action of FGF23 in vivo have remained elusive. In this study, we show that proximal tubules express FGFR1, −3, and −4 but not FGFR2 mRNA. To determine which of these three FGFRs mediates FGF23's hypophosphatemic actions, we characterized phosphate homeostasis in FGFR3−/−and FGFR4−/−null mice, and in conditional FGFR1−/−mice, with targeted deletion of FGFR1 expression in the metanephric mesenchyme. Basal serum phosphorus levels and renal cortical brush-border membrane (BBM) NaPi-2a and NaPi-2c expression were comparable between FGFR1−/−, FGFR3−/−, and FGFR4−/−mice and their wild-type counterparts. Administration of FGF23 to FGFR3−/−mice induced hypophosphatemia in these mice (8.0 ± 0.4 vs. 5.4 ± 0.3 mg/dl; p ≤ 0.001) and a decrease in renal BBM NaPi-2a and NaPi-2c protein expression. Similarly, in FGFR4−/−mice, administration of FGF23 caused a small but significant decrease in serum phosphorus levels (8.7 ± 0.3 vs. 7.6 ± 0.4 mg/dl; p ≤ 0.001) and in renal BBM NaPi-2a and NaPi-2c protein abundance. In contrast, injection of FGF23 into FGFR1−/−mice had no effects on serum phosphorus levels (5.6 ± 0.3 vs. 5.2 ± 0.5 mg/dl) or BBM NaPi-2a and NaPi-2c expression. These data show that FGFR1 is the predominant receptor for the hypophosphatemic action of FGF23 in vivo, with FGFR4 likely playing a minor role.
- Published
- 2009
- Full Text
- View/download PDF
21. Understanding the Molecular Basis of Apert Syndrome
- Author
-
Ibrahimi, Omar A., Chiu, Ernest S., McCarthy, Joseph G., and Mohammadi, Moosa
- Abstract
Apert syndrome, first described in 1906, is one of the most severe of the craniosynostosis syndromes and is further characterized by midface hypoplasia, syndactyly, and other visceral abnormalities. Affected individuals generally require lifelong management by a multidisciplinary team of health care specialists. Apert syndrome results almost exclusively from one or the other of two point mutations in fibroblast growth factor receptor 2. Tremendous scientific advances have been made recently in understanding the molecular basis for Apert syndrome through clinical genetic, biochemical, and structural approaches. In this review, the authors provide the clinician with a basic overview of these findings and their therapeutic implications.
- Published
- 2005
- Full Text
- View/download PDF
22. Structural Basis for Activation of Fibroblast Growth Factor Signaling by Sucrose Octasulfate
- Author
-
Yeh, Brian K., Eliseenkova, Anna V., Plotnikov, Alexander N., Green, David, Pinnell, Jared, Polat, Tulay, Gritli-Linde, Amel, Linhardt, Robert J., and Mohammadi, Moosa
- Abstract
ABSTRACTSucrose octasulfate (SOS) is believed to stimulate fibroblast growth factor (FGF) signaling by binding and stabilizing FGFs. In this report, we show that SOS induces FGF-dependent dimerization of FGF receptors (FGFRs). The crystal structure of the dimeric FGF2-FGFR1-SOS complex at 2.6-Å resolution reveals a symmetric assemblage of two 1:1:1 FGF2-FGFR1-SOS ternary complexes. Within each ternary complex SOS binds to FGF and FGFR and thereby increases FGF-FGFR affinity. SOS also interacts with the adjoining FGFR and thereby promotes protein-protein interactions that stabilize dimerization. This structural finding is supported by the inability of selectively desulfated SOS molecules to promote receptor dimerization. Thus, we propose that SOS potentiates FGF signaling by imitating the dual role of heparin in increasing FGF-FGFR affinity and promoting receptor dimerization. Hence, the dimeric FGF-FGFR-SOS structure substantiates the recently proposed “two-end” model, by which heparin induces FGF-FGFR dimerization. Moreover, the FGF-FGFR-SOS structure provides an attractive template for the development of easily synthesized SOS-related heparin agonists and antagonists that may hold therapeutic potential.
- Published
- 2002
- Full Text
- View/download PDF
23. Structural Basis for Activation of Fibroblast Growth Factor Signaling by Sucrose Octasulfate
- Author
-
Yeh, Brian K., Eliseenkova, Anna V., Plotnikov, Alexander N., Green, David, Pinnell, Jared, Polat, Tulay, Gritli-Linde, Amel, Linhardt, Robert J., and Mohammadi, Moosa
- Abstract
Sucrose octasulfate (SOS) is believed to stimulate fibroblast growth factor (FGF) signaling by binding and stabilizing FGFs. In this report, we show that SOS induces FGF-dependent dimerization of FGF receptors (FGFRs). The crystal structure of the dimeric FGF2-FGFR1-SOS complex at 2.6-Å resolution reveals a symmetric assemblage of two 1:1:1 FGF2-FGFR1-SOS ternary complexes. Within each ternary complex SOS binds to FGF and FGFR and thereby increases FGF-FGFR affinity. SOS also interacts with the adjoining FGFR and thereby promotes protein-protein interactions that stabilize dimerization. This structural finding is supported by the inability of selectively desulfated SOS molecules to promote receptor dimerization. Thus, we propose that SOS potentiates FGF signaling by imitating the dual role of heparin in increasing FGF-FGFR affinity and promoting receptor dimerization. Hence, the dimeric FGF-FGFR-SOS structure substantiates the recently proposed “two-end” model, by which heparin induces FGF-FGFR dimerization. Moreover, the FGF-FGFR-SOS structure provides an attractive template for the development of easily synthesized SOS-related heparin agonists and antagonists that may hold therapeutic potential.
- Published
- 2002
- Full Text
- View/download PDF
24. Identification of Receptor and Heparin Binding Sites in Fibroblast Growth Factor 4 by Structure-Based Mutagenesis
- Author
-
Bellosta, Paola, Iwahori, Akiyo, Plotnikov, Alexander N., Eliseenkova, Anna V., Basilico, Claudio, and Mohammadi, Moosa
- Abstract
Fibroblast growth factors (FGFs) comprise a large family of multifunctional, heparin-binding polypeptides that show diverse patterns of interaction with a family of receptors (FGFR1 to -4) that are subject to alternative splicing. FGFR binding specificity is an essential mechanism in the regulation of FGF signaling and is achieved through primary sequence differences among FGFs and FGFRs and through usage of two alternative exons, IIIc and IIIb, for the second half of immunoglobulin-like domain 3 (D3) in FGFRs. While FGF4 binds and activates the IIIc splice forms of FGFR1 to -3 at comparable levels, it shows little activity towards the IIIb splice forms of FGFR1 to -3 as well as towards FGFR4. To begin to explore the structural determinants for this differential affinity, we determined the crystal structure of FGF4 at a 1.8-Å resolution. FGF4 adopts a β-trefoil fold similar to other FGFs. To identify potential receptor and heparin binding sites in FGF4, a ternary FGF4-FGFR1-heparin model was constructed by superimposing the FGF4 structure onto FGF2 in the FGF2-FGFR1-heparin structure. Mutation of several key residues in FGF4, observed to interact with FGFR1 or with heparin in the model, produced ligands with reduced receptor binding and concomitant low mitogenic potential. Based on the modeling and mutational data, we propose that FGF4, like FGF2, but unlike FGF1, engages the βC′-βE loop in D3 and thus can differentiate between the IIIc and IIIb splice isoforms of FGFRs for binding. Moreover, we show that FGF4 needs to interact with both the 2-O- and 6-O-sulfates in heparin to exert its optimal biological activity.
- Published
- 2001
- Full Text
- View/download PDF
25. Identification of Receptor and Heparin Binding Sites in Fibroblast Growth Factor 4 by Structure-Based Mutagenesis
- Author
-
Bellosta, Paola, Iwahori, Akiyo, Plotnikov, Alexander N., Eliseenkova, Anna V., Basilico, Claudio, and Mohammadi, Moosa
- Abstract
ABSTRACTFibroblast growth factors (FGFs) comprise a large family of multifunctional, heparin-binding polypeptides that show diverse patterns of interaction with a family of receptors (FGFR1 to -4) that are subject to alternative splicing. FGFR binding specificity is an essential mechanism in the regulation of FGF signaling and is achieved through primary sequence differences among FGFs and FGFRs and through usage of two alternative exons, IIIc and IIIb, for the second half of immunoglobulin-like domain 3 (D3) in FGFRs. While FGF4 binds and activates the IIIc splice forms of FGFR1 to -3 at comparable levels, it shows little activity towards the IIIb splice forms of FGFR1 to -3 as well as towards FGFR4. To begin to explore the structural determinants for this differential affinity, we determined the crystal structure of FGF4 at a 1.8-Å resolution. FGF4 adopts a β-trefoil fold similar to other FGFs. To identify potential receptor and heparin binding sites in FGF4, a ternary FGF4-FGFR1-heparin model was constructed by superimposing the FGF4 structure onto FGF2 in the FGF2-FGFR1-heparin structure. Mutation of several key residues in FGF4, observed to interact with FGFR1 or with heparin in the model, produced ligands with reduced receptor binding and concomitant low mitogenic potential. Based on the modeling and mutational data, we propose that FGF4, like FGF2, but unlike FGF1, engages the βC′-βE loop in D3 and thus can differentiate between the IIIc and IIIb splice isoforms of FGFRs for binding. Moreover, we show that FGF4 needs to interact with both the 2-O- and 6-O-sulfates in heparin to exert its optimal biological activity.
- Published
- 2001
- Full Text
- View/download PDF
26. Crystal Structure of Fibroblast Growth Factor 9 Reveals Regions Implicated in Dimerization and Autoinhibition*
- Author
-
Plotnikov, Alexander N., Eliseenkova, Anna V., Ibrahimi, Omar A., Shriver, Zachary, Sasisekharan, Ram, Lemmon, Mark A., and Mohammadi, Moosa
- Abstract
Fibroblast growth factors (FGFs) constitute a large family of heparin-binding growth factors with diverse biological activities. FGF9 was originally described as glia-activating factor and is expressed in the nervous system as a potent mitogen for glia cells. Unlike most FGFs, FGF9 forms dimers in solution with a Kdof 680 nm. To elucidate the molecular mechanism of FGF9 dimerization, the crystal structure of FGF9 was determined at 2.2 Å resolution. FGF9 adopts a β-trefoil fold similar to other FGFs. However, unlike other FGFs, the N- and C-terminal regions outside the β-trefoil core in FGF9 are ordered and involved in the formation of a 2-fold crystallographic dimer. A significant surface area (>2000 Å2) is buried in the dimer interface that occludes a major receptor binding site of FGF9. Thus, we propose an autoinhibitory mechanism for FGF9 that is dependent on sequences outside of the β-trefoil core. Moreover, a model is presented providing a molecular basis for the preferential affinity of FGF9 toward FGFR3.
- Published
- 2001
- Full Text
- View/download PDF
27. Different Tyrosine Autophosphorylation Requirements in Fibroblast Growth Factor Receptor-1 Mediate Urokinase-Type Plasminogen Activator Induction and Mitogenesis
- Author
-
Dell’Era, Patrizia, Mohammadi, Moosa, and Presta, Marco
- Abstract
Among the seven tyrosine autophosphorylation sites identified in the intracellular domain of tyrosine kinase fibroblast growth factor receptor-1 (FGFR1), five of them are dispensable for FGFR1-mediated mitogenic signaling. The possibility of dissociating the mitogenic activity of basic FGF (FGF2) from its urokinase-type plasminogen activator (uPA)-inducing capacity both at pharmacological and structural levels prompted us to evaluate the role of these autophosphorylation sites in transducing FGF2-mediated uPA upregulation. To this purpose, L6 myoblasts transfected with either wild-type (wt) or various FGFR1 mutants were evaluated for the capacity to upregulate uPA production by FGF2. uPA was induced in cells transfected with wt-FGFR1, FGFR1-Y463F, -Y585F, -Y730F, -Y766F, or -Y583/585F mutants. In contrast, uPA upregulation was prevented in L6 cells transfected with FGFR1-Y463/583/585/730F mutant (FGFR1–4F) or with FGFR1-Y463/583/585/730/766F mutant (FGFR1–5F) that retained instead a full mitogenic response to FGF2; however, preservation of residue Y730 in FGFR1-Y463/583/585F mutant (FGFR1–3F) and FGFR1-Y463/583/585/766F mutant (FGFR1–4Fbis) allows the receptor to transduce uPA upregulation. Wild-type FGFR1, FGFR1–3F, and FGFR1–4F similarly bind to a 90-kDa tyrosine-phosphorylated protein and activate Shc, extracellular signal-regulated kinase (ERK)2, and JunD after stimulation with FGF2. These data, together with the capacity of the ERK kinase inhibitor PD 098059 to prevent ERK2activation and uPA upregulation in wt-FGFR1 cells, suggest that signaling through the Ras/Raf-1/ERK kinase/ERK/JunD pathway is necessary but not sufficient for uPA induction in L6 transfectants. Accordingly, FGF2 was able to stimulate ERK1/2phosphorylation and cell proliferation, but not uPA upregulation, in L6 cells transfected with the FGFR1-Y463/730F mutant, whereas the FGFR1-Y583/585/730F mutant was fully active. We conclude that different tyrosine autophosphorylation requirements in FGFR1 mediate cell proliferation and uPA upregulation induced by FGF2 in L6 cells. In particular, phosphorylation of either Y463 or Y730, dispensable for mitogenic signaling, represents an absolute requirement for FGF2-mediated uPA induction.
- Published
- 1999
- Full Text
- View/download PDF
28. Induction of Urokinase-type Plasminogen Activator by Fibroblast Growth Factor (FGF)-2 Is Dependent on Expression of FGF Receptors and Does Not Require Activation of Phospholipase Cγ1*
- Author
-
Roghani, Monireh, Mohammadi, Moosa, Schlessinger, Joseph, and Moscatelli, David
- Abstract
The roles of heparan sulfate proteoglycans and tyrosine kinase fibroblast growth factor (FGF) receptors in mediating the induction of plasminogen activator (PA) by FGF-2 were investigated using L6 myoblast cells that normally do not express detectable FGF receptors. PA was induced by FGF-2 in a dose-dependent manner in L6 cells expressing transfected FGF receptor-1 but not in nontransfected cells or cells transfected with the vector alone. The PA produced in these cells was characterized as urokinase-type PA (uPA). Thus, expression of a tyrosine kinase FGF receptor was required for induction of uPA. Internalization of FGF through heparan sulfates does not seem to be involved in this response as soluble heparin and suramin at concentrations which inhibited FGF-2 binding to heparan sulfates but not receptors did not affect the induction of uPA by FGF-2. Mutant receptors in which the tyrosine kinase was inactivated were not able to respond to FGF-2. In contrast, mutation of the site of phospholipase Cγ1 (PLCγ) binding in the receptor, which causes loss of PLCγ activation, had no effect on uPA induction by FGF-2. These results suggest that PLCγ activation is not required for induction of uPA by FGF-2.
- Published
- 1996
- Full Text
- View/download PDF
29. Reduced Activation of RAF-1 and MAP Kinase by a Fibroblast Growth Factor Receptor Mutant Deficient in Stimulation of Phosphatidylinositol Hydrolysis (∗)
- Author
-
Huang, Jiaoti, Mohammadi, Moosa, Rodrigues, Gerard A., and Schlessinger, Joseph
- Abstract
Signaling via the fibroblast growth factor receptor 1 (FGFR1, flg) was analyzed in Ba/F3 hematopoietic cells expressing either wild-type or a mutant FGF receptor (Y766F) unable to activate phospholipase C-γ (PLC-γ) and stimulate phosphatidylinositol (PI) hydrolysis. Stimulation of cells expressing wild-type or mutant FGFR with acidic FGF (aFGF) caused similar activation of Ras. However, an approximately 3-fold reduced activation of Raf-1 and MAP kinase was observed in aFGF-stimulated cells expressing mutant receptors as compared to cells expressing wild-type FGF receptors. Comparison of phosphopeptide maps of Raf-1 immunoprecipitated from the two cell types activated by either aFGF or the phorbol ester (12-O-tetradecanoylphorbol-13-acetate) suggests that Raf-1 is phosphorylated by both Ras-dependent and PLC-γ-dependent mechanisms. In spite of the differential effect on Raf-1 and MAP kinase activation, aFGF stimulated similar proliferation of cells expressing wild-type or mutant receptors indicating that Ras-dependent activation of Raf-1 and MAP kinase is sufficient for transduction of FGFR mitogenic signals. Ras may also activate signal transduction pathways that are complementary or parallel to the MAP kinase pathway to stimulate cell proliferation.
- Published
- 1995
- Full Text
- View/download PDF
30. Autoregulatory Mechanisms in Protein-tyrosine Kinases*
- Author
-
Hubbard, Stevan R., Mohammadi, Moosa, and Schlessinger, Joseph
- Published
- 1998
- Full Text
- View/download PDF
31. Synthesis of sulfosucrose derivatives for evaluation as regulators of fibroblast growth factor activity
- Author
-
Polat, Tu¨lay, Mohammadi, Moosa, and Linhardt, Robert J.
- Abstract
Based on X-ray crystallographic studies on sucrose octasulfate in complex with fibroblast growth factor and its receptor, three analogs of sucrose octasulfate were regioselectively synthesized for biological evaluation as regulations of cell proliferation and differentiation.
- Published
- 2002
- Full Text
- View/download PDF
32. Characterization of Disease Causing Mutations Associated with FGF Receptor Tyrosine Kinases using NMR Spectroscopy
- Author
-
Marsiglia, William M., Chen, Huaibin, Cho, Min-kyu, Mohammadi, Moosa, and Traaseth, Nathaniel J.
- Published
- 2017
- Full Text
- View/download PDF
33. NMR Experiments on Wild-Type and Mutant Fibroblast Growth Factor Receptor Kinases Reveal Conformational Dynamics Associated with Enzyme Activation
- Author
-
Marsiglia, William, Chen, Huaibin, Cho, Min-kyu, Mohammadi, Moosa, and Traaseth, Nathaniel J.
- Published
- 2016
- Full Text
- View/download PDF
34. Grb2, a Double-Edged Sword of Receptor Tyrosine Kinase Signaling
- Author
-
Belov, Artur A. and Mohammadi, Moosa
- Abstract
The adaptor Grb2 plays both positive and negative roles in FGF receptor signaling.
- Published
- 2012
- Full Text
- View/download PDF
35. Nonsense Mutations in FGF8 Gene Causing Different Degrees of Human Gonadotropin-Releasing Deficiency
- Author
-
Trarbach, Ericka B., Abreu, Ana Paula, Silveira, Leticia Ferreira Gontijo, Garmes, Heraldo Mendes, Baptista, Maria Tereza M., Teles, Milena Gurgel, Costa, Elaine M. F., Mohammadi, Moosa, Pitteloud, Nelly, Mendonca, Berenice B., and Latronico, Ana Claudia
- Published
- 2010
36. Frequency of Impaired Fibroblast Growth Factor Receptor 1 Signaling as a Cause of Normosmic Idiopathic Hypogonadotropic Hypogonadism.
- Author
-
Raivio, Taneli, Sidis, Yisrael, Plummer, Lacey, Chen, Huaibin, Ma, Jinghong, Mukherjee, Abir, Jacobson-Dickman, Elka, Quinton, Richard, Van Vliet, Guy, Lavoie, Helene, Hughes, Virginia A, Dwyer, Andrew, Hayes, Frances J, Xu, Shuyun, Sparks, Susan, Kaiser, Ursula B, Mohammadi, Moosa, and Pitteloud, Nelly
- Published
- 2009
- Full Text
- View/download PDF
37. Differential Interactions of FGFs with Heparan Sulfate Control Gradient Formation and Branching Morphogenesis
- Author
-
Makarenkova, Helen P., Hoffman, Matthew P., Beenken, Andrew, Eliseenkova, Anna V., Meech, Robyn, Tsau, Cindy, Patel, Vaishali N., Lang, Richard A., and Mohammadi, Moosa
- Abstract
Manipulation of the interaction of a morphogen with the extracellular matrix changes its biological activities by altering its diffusion.
- Published
- 2009
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.